Merck & Co. has become a standout player in the Dow thanks to its steady revenue streams and hedge fund popularity. It ranks ...

We can contribute innovation globally,” Xia says. “I think that's very satisfying.” As director general of the World Health ...

We recently published a list of The Best and Worst Dow Stocks. In this article, we are going to take a look at where Merck & ...

Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

We recently published a list of Billionaire Mario Gabelli’s 10 Large-Cap Stock Picks with Huge Upside Potential. In this ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

New Jersey-based pharmaceutical giant Merck is investing $1 billion in what company executives described as a continued ...

WILMINGTON, Del., May 06, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for first quarter ...

The S&P 500, the Dow Jones, and the NASDAQ all moved between 0.8% and 1% lower by mid-afternoon. Palantir (PLTR) stock ...

U.S. pharmaceutical imports surged in March, exceeding $50 billion, as drugmakers stockpiled inventory in anticipation of ...

The 470,000-square-foot facility will support the launch and commercial production of next-generation biologics and therapies ...